Tonix Pharmaceuticals Holding (TNXP) Total Non-Current Liabilities (2011 - 2023)
Tonix Pharmaceuticals Holding's (TNXP) quarterly Total Non-Current Liabilities came in at $40.7 million in Q4 2023, up 12901.64% quarter-over-quarter from $312822.0 in Q1 2012.
Tonix Pharmaceuticals Holding (TNXP) Total Non-Current Liabilities (2011 - 2023) Analysis & Trends
Tonix Pharmaceuticals Holding's Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $40.7 million for Q4 2023.
- On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $40.7 million in Q4 2023; TTM through Dec 2023 was $40.7 million, a N/A change from a year earlier, with the FY2023 full-year figure at $40.7 million, changed N/A from the prior year.
- Total Non-Current Liabilities advanced to $40.7 million in Q4 2023 per TNXP's latest filing, from $312822.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $40.7 million in Q4 2023 and bottomed at $40.7 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Tonix Pharmaceuticals Holding | 142.14 Mn | 142.14 Mn | 5.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 40.67 Mn |
| Mar 31, 2012 | 312,822.00 |
| Dec 31, 2011 | 2.88 Mn |